FDA Warns Online Vendors to Stop Selling Unapproved Weight-Loss Drugs
The FDA on Tuesday published letters warning two online vendors to stop selling unapproved versions of semaglutide and tirzepatide.
Stay updated with breaking news from Gorilla Healing. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The FDA on Tuesday published letters warning two online vendors to stop selling unapproved versions of semaglutide and tirzepatide.
FDA issued warning letters to two online retailers, Semaspace and Gorilla Healing, instructing them to cease selling unapproved versions of semaglutide and tirzepatide
The U.S. Food and Drug Administration (FDA) on Tuesday published letters warning two online vendors to stop selling unapproved versions of semaglutide and tirzepatide, the active ingredients in popular GLP-1 class medications including Novo Nordisk’s powerful weight-loss drug Wegovy. In the letters sent to Semaspace and Gorilla Healing on Oct. 2, the FDA said the only approved semaglutide products were Wegovy and Novo’s diabetes drugs Ozempic and Rybelsus.
FDA issued warning letters to two online retailers, Semaspace and Gorilla Healing, instructing them to cease selling unapproved versions of semaglutide and tirzepatide